Trevi Therapeutics, Inc. (TRVI)

TRVI price $13.04 +0.27 +2.08%

Ticker
TRVI
Price
$13.04
Change
+0.27 +2.08%
Market cap
$1.86B
P/E
-37.98
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
67

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with…

Stocklytics home · Screener